BCL-6 and the Molecular Pathogenesis of B-Cell Lymphoma
- R. Dalla-Favera*,
- B.H. Ye*,
- F. Lo Coco*,
- C.-C. Chang*,
- K. Cechova*,
- J. Zhang*,
- A. Migliazza*,
- W. Mellado*,
- H. Niu*,
- S. Chaganti†,
- W. Chen†,
- P.H. Rao†,
- N.Z. Parsa†,
- D.C. Louie†,
- K. Offit†, and
- R.S.K. Chaganti†
- *Division of Oncology, Department of Pathology, and Department of Genetics and Development, College of Physicians & Surgeons, Columbia University, New York, New York 10032; †Cell Biology and Genetics Program, and the Departments of Human Genetics and Pathology and Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
This extract was created in the absence of an abstract.
Excerpt
Non-Hodgkin's lymphomas (NHL) include a group of neoplasms which share a common target tissue, lymphoid cells, yet are characterized by a high degree of biological and clinical heterogeneity (for review, see Magrath 1990). Most NHL derive from the B-cell lineage and, in particular, from mature B cells, which are characterized by rearranged immunoglobulin (Ig) heavy- (IgH) and light-chain genes and by the expression of cell-surface Ig and B-cell-associated markers. NHL are usually classified according to their degree of clinical aggressiveness correlated with their stage of differentiation and pattern of growth: Low-grade NHL include small lymphocytic lymphoma (SLL) and the majority of follicular lymphomas (FL); intermediate-grade NHL include a subset of FL and diffuse large cell lymphoma (DLCL); high-grade NHL include immuno-blastic and lymphoblastic NHL as well as Burkitt's lymphomas (BL).
The wide clinico-pathological heterogeneity of NHL is reflected at the cellular level by the variety of molecular pathways underlying NHL...
